[Skip to Navigation]
February 12, 2020

Sexual and Gender Minority Populations and Skin Cancer—New Data and Renewed Priorities

Author Affiliations
  • 1Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia
  • 2Regional Telehealth Service, Virginia Southeast Network VISN 7, Decatur, Georgia
  • 3Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia
JAMA Dermatol. 2020;156(4):367-369. doi:10.1001/jamadermatol.2019.4174

Sexual and gender minority (SGM) persons include, but are not limited to, individuals who identify as lesbian, gay, bisexual, or transgender, as well as individuals whose sexual orientation, gender identity or expression, or reproductive development are characterized by nonbinary constructs of sexual orientation, gender, and/or sex.1 The National Cancer Institute (NCI) has called for specific research to “assess cancer risk to inform improved decision-making, risk reduction interventions, and screening options for early cancer detection in SGM populations.”1 Notably, population-based data on skin cancer epidemiology in SGM persons remain inadequate. Without robust epidemiologic data, it has been challenging for dermatologists to recognize and articulate their specific roles within broader national conversations on improving SGM health. Emerging skin cancer data, particularly among gay and bisexual men, indicate unmet needs for skin cancer prevention in specific SGM subpopulations.2

Add or change institution